The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
John DiPersio, MD, PhD, and Phillip Scheinberg, MD, PhD, reflect on the first SOHO Central Europe, which was held in Budapest October 9-10. “I thought
The designation was granted based on preliminary findings from the ongoing phase 1/2 Horizen-1 study (NCT04988555). Clinical trial evidence indicated that the therapy may demonstrate substantial improvement over available options on clinically significant endpoints, according to a press release from Sumitomo Pharma America, the developer of the drug.
In a recent analysis, STAT reported that the NIH spent its entire external grants budget of $34 billion in FY2026 but noted the number of projects funded has been falling in recent years. Furthermore, STAT reported, funding processes are opaque, leaving even seasoned academics “unsure their ideas will be funded until they receive final notices.”
CR/VGPR rates were also not impacted by the presence of CXCR4 or TP53 mutations, wrote the study’s lead author, Andrew P. Branagan, MD, PhD, of Mass General Brigham Cancer Institute in Boston.
In the second part of this two-video series, Guillermo Garcia-Manero, MD, continues his discussion of lower-risk myelodysplastic syndromes with SOHO young investigators during SOHO 2026.
A Biologics License Application was submitted to the US Food and Drug Administration for the BCMA-directed, 2nd-generation bispecific antibody etentamig for the treatment of relapsed or refractory multiple myeloma, as reported by the drug’s manufacturer, AbbVie.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
